C80-A EVERYTHING YOU NEED TO KNOW ABOUT BRONCHOPULMONARY DYSPLASIA, CYSTIC FIBROSIS AND DIFFUSE PARENCHYMAL LUNG DISEASES: Enac Inhibitor Azd5634 Augments Airway Surface Liquid And Mucociliary Transport In Primary Cystic Fibrosis Airway Cells

C80-A EVERYTHING YOU NEED TO KNOW ABOUT BRONCHOPULMONARY DYSPLASIA, CYSTIC FIBROSIS AND DIFFUSE PARENCHYMAL LUNG DISEASES: Enac Inhibitor Azd5634 Augments Airway Surface Liquid And Mucociliary Transport In Primary Cystic Fibrosis Airway Cells

The Cystic Fibrosis (CF) airway is dehydrated due to impaired Cl" secretion resulting from defective cystic fibrosis transmembrane conductance regulator (CFTR) function coupled with persistent Na+ absorption through the epithelial sodium channel (ENaC), which contributes to reduced mucociliary...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of respiratory and critical care medicine 2017-01, Vol.195
Hauptverfasser: Libby, E Falk, tinberry, H, Birket, S, Astrand, A, Patel, N, Malmgren, A, Tearney, G J, Rowe, S
Format: Artikel
Sprache:eng
Schlagworte:
Cystic fibrosis
Lung diseases
Sodium
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title American journal of respiratory and critical care medicine
container_volume 195
creator Libby, E Falk
tinberry, H
Birket, S
Astrand, A
Patel, N
Malmgren, A
Tearney, G J
Rowe, S
description The Cystic Fibrosis (CF) airway is dehydrated due to impaired Cl" secretion resulting from defective cystic fibrosis transmembrane conductance regulator (CFTR) function coupled with persistent Na+ absorption through the epithelial sodium channel (ENaC), which contributes to reduced mucociliary clearance. A novel ENaC inhibitor compound (AZD5634) with poor airway epithelial absorption and high affinity for ENaC has been developed, and the purpose of these studies was to evaluate its effect on airway surface liquid (ASL) and mucus transport in CF in vitro.
format Article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_1926863615</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1926863615</sourcerecordid><originalsourceid>FETCH-proquest_journals_19268636153</originalsourceid><addsrcrecordid>eNqNkM1Og0AURonRxPrzDjdxKwkUSlt302GQiZQhDKisGkqpTkOhnYGY-tg-gWNiXLv6bu499yy-M2NkT5yJ6c6n1rmeraljuu789dK4UmpnWfZ4Zlsj4wvPLBMBeSZpkYU0foSC5RAT4kPG4ClmL4AWLM9gkbIYhyzJoyWLUVqAX_AkQpyie8AFzyiGgGqIUw4o9sGnQZBzAglKiX4sliiCKNd-n3KCOOEPQNqyAtq-i7XoOwnoczPxHBfQ8Lav214BEvKjPAEf5LasaojEcRAbQO0GlkPVVaIRpTxBJstWHTrZaxUkUux_lvikelFBINayU-JPheumUTfGxbZsVH37m9fGXUAyHJoH2R2HWvWrXTfIVp9W9nzszTzH003-j_oGAUBvTw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1926863615</pqid></control><display><type>article</type><title>C80-A EVERYTHING YOU NEED TO KNOW ABOUT BRONCHOPULMONARY DYSPLASIA, CYSTIC FIBROSIS AND DIFFUSE PARENCHYMAL LUNG DISEASES: Enac Inhibitor Azd5634 Augments Airway Surface Liquid And Mucociliary Transport In Primary Cystic Fibrosis Airway Cells</title><source>Journals@Ovid Complete</source><source>American Thoracic Society (ATS) Journals Online</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Libby, E Falk ; tinberry, H ; Birket, S ; Astrand, A ; Patel, N ; Malmgren, A ; Tearney, G J ; Rowe, S</creator><creatorcontrib>Libby, E Falk ; tinberry, H ; Birket, S ; Astrand, A ; Patel, N ; Malmgren, A ; Tearney, G J ; Rowe, S</creatorcontrib><description>The Cystic Fibrosis (CF) airway is dehydrated due to impaired Cl" secretion resulting from defective cystic fibrosis transmembrane conductance regulator (CFTR) function coupled with persistent Na+ absorption through the epithelial sodium channel (ENaC), which contributes to reduced mucociliary clearance. A novel ENaC inhibitor compound (AZD5634) with poor airway epithelial absorption and high affinity for ENaC has been developed, and the purpose of these studies was to evaluate its effect on airway surface liquid (ASL) and mucus transport in CF in vitro.</description><identifier>ISSN: 1073-449X</identifier><identifier>EISSN: 1535-4970</identifier><language>eng</language><publisher>New York: American Thoracic Society</publisher><subject>Cystic fibrosis ; Lung diseases ; Sodium</subject><ispartof>American journal of respiratory and critical care medicine, 2017-01, Vol.195</ispartof><rights>Copyright American Thoracic Society 2017</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids></links><search><creatorcontrib>Libby, E Falk</creatorcontrib><creatorcontrib>tinberry, H</creatorcontrib><creatorcontrib>Birket, S</creatorcontrib><creatorcontrib>Astrand, A</creatorcontrib><creatorcontrib>Patel, N</creatorcontrib><creatorcontrib>Malmgren, A</creatorcontrib><creatorcontrib>Tearney, G J</creatorcontrib><creatorcontrib>Rowe, S</creatorcontrib><title>C80-A EVERYTHING YOU NEED TO KNOW ABOUT BRONCHOPULMONARY DYSPLASIA, CYSTIC FIBROSIS AND DIFFUSE PARENCHYMAL LUNG DISEASES: Enac Inhibitor Azd5634 Augments Airway Surface Liquid And Mucociliary Transport In Primary Cystic Fibrosis Airway Cells</title><title>American journal of respiratory and critical care medicine</title><description>The Cystic Fibrosis (CF) airway is dehydrated due to impaired Cl" secretion resulting from defective cystic fibrosis transmembrane conductance regulator (CFTR) function coupled with persistent Na+ absorption through the epithelial sodium channel (ENaC), which contributes to reduced mucociliary clearance. A novel ENaC inhibitor compound (AZD5634) with poor airway epithelial absorption and high affinity for ENaC has been developed, and the purpose of these studies was to evaluate its effect on airway surface liquid (ASL) and mucus transport in CF in vitro.</description><subject>Cystic fibrosis</subject><subject>Lung diseases</subject><subject>Sodium</subject><issn>1073-449X</issn><issn>1535-4970</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqNkM1Og0AURonRxPrzDjdxKwkUSlt302GQiZQhDKisGkqpTkOhnYGY-tg-gWNiXLv6bu499yy-M2NkT5yJ6c6n1rmeraljuu789dK4UmpnWfZ4Zlsj4wvPLBMBeSZpkYU0foSC5RAT4kPG4ClmL4AWLM9gkbIYhyzJoyWLUVqAX_AkQpyie8AFzyiGgGqIUw4o9sGnQZBzAglKiX4sliiCKNd-n3KCOOEPQNqyAtq-i7XoOwnoczPxHBfQ8Lav214BEvKjPAEf5LasaojEcRAbQO0GlkPVVaIRpTxBJstWHTrZaxUkUux_lvikelFBINayU-JPheumUTfGxbZsVH37m9fGXUAyHJoH2R2HWvWrXTfIVp9W9nzszTzH003-j_oGAUBvTw</recordid><startdate>20170101</startdate><enddate>20170101</enddate><creator>Libby, E Falk</creator><creator>tinberry, H</creator><creator>Birket, S</creator><creator>Astrand, A</creator><creator>Patel, N</creator><creator>Malmgren, A</creator><creator>Tearney, G J</creator><creator>Rowe, S</creator><general>American Thoracic Society</general><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20170101</creationdate><title>C80-A EVERYTHING YOU NEED TO KNOW ABOUT BRONCHOPULMONARY DYSPLASIA, CYSTIC FIBROSIS AND DIFFUSE PARENCHYMAL LUNG DISEASES: Enac Inhibitor Azd5634 Augments Airway Surface Liquid And Mucociliary Transport In Primary Cystic Fibrosis Airway Cells</title><author>Libby, E Falk ; tinberry, H ; Birket, S ; Astrand, A ; Patel, N ; Malmgren, A ; Tearney, G J ; Rowe, S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_19268636153</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Cystic fibrosis</topic><topic>Lung diseases</topic><topic>Sodium</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Libby, E Falk</creatorcontrib><creatorcontrib>tinberry, H</creatorcontrib><creatorcontrib>Birket, S</creatorcontrib><creatorcontrib>Astrand, A</creatorcontrib><creatorcontrib>Patel, N</creatorcontrib><creatorcontrib>Malmgren, A</creatorcontrib><creatorcontrib>Tearney, G J</creatorcontrib><creatorcontrib>Rowe, S</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>American journal of respiratory and critical care medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Libby, E Falk</au><au>tinberry, H</au><au>Birket, S</au><au>Astrand, A</au><au>Patel, N</au><au>Malmgren, A</au><au>Tearney, G J</au><au>Rowe, S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>C80-A EVERYTHING YOU NEED TO KNOW ABOUT BRONCHOPULMONARY DYSPLASIA, CYSTIC FIBROSIS AND DIFFUSE PARENCHYMAL LUNG DISEASES: Enac Inhibitor Azd5634 Augments Airway Surface Liquid And Mucociliary Transport In Primary Cystic Fibrosis Airway Cells</atitle><jtitle>American journal of respiratory and critical care medicine</jtitle><date>2017-01-01</date><risdate>2017</risdate><volume>195</volume><issn>1073-449X</issn><eissn>1535-4970</eissn><abstract>The Cystic Fibrosis (CF) airway is dehydrated due to impaired Cl" secretion resulting from defective cystic fibrosis transmembrane conductance regulator (CFTR) function coupled with persistent Na+ absorption through the epithelial sodium channel (ENaC), which contributes to reduced mucociliary clearance. A novel ENaC inhibitor compound (AZD5634) with poor airway epithelial absorption and high affinity for ENaC has been developed, and the purpose of these studies was to evaluate its effect on airway surface liquid (ASL) and mucus transport in CF in vitro.</abstract><cop>New York</cop><pub>American Thoracic Society</pub></addata></record>
fulltext fulltext
identifier ISSN: 1073-449X
ispartof American journal of respiratory and critical care medicine, 2017-01, Vol.195
issn 1073-449X
1535-4970
language eng
recordid cdi_proquest_journals_1926863615
source Journals@Ovid Complete; American Thoracic Society (ATS) Journals Online; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects Cystic fibrosis
Lung diseases
Sodium
title C80-A EVERYTHING YOU NEED TO KNOW ABOUT BRONCHOPULMONARY DYSPLASIA, CYSTIC FIBROSIS AND DIFFUSE PARENCHYMAL LUNG DISEASES: Enac Inhibitor Azd5634 Augments Airway Surface Liquid And Mucociliary Transport In Primary Cystic Fibrosis Airway Cells
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T23%3A06%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=C80-A%20EVERYTHING%20YOU%20NEED%20TO%20KNOW%20ABOUT%20BRONCHOPULMONARY%20DYSPLASIA,%20CYSTIC%20FIBROSIS%20AND%20DIFFUSE%20PARENCHYMAL%20LUNG%20DISEASES:%20Enac%20Inhibitor%20Azd5634%20Augments%20Airway%20Surface%20Liquid%20And%20Mucociliary%20Transport%20In%20Primary%20Cystic%20Fibrosis%20Airway%20Cells&rft.jtitle=American%20journal%20of%20respiratory%20and%20critical%20care%20medicine&rft.au=Libby,%20E%20Falk&rft.date=2017-01-01&rft.volume=195&rft.issn=1073-449X&rft.eissn=1535-4970&rft_id=info:doi/&rft_dat=%3Cproquest%3E1926863615%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1926863615&rft_id=info:pmid/&rfr_iscdi=true